株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

消化管間質腫瘍 (GIST):パイプライン製品の分析

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 229743
出版日 ページ情報 英文 258 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.28円で換算しております。
Back to Top
消化管間質腫瘍 (GIST):パイプライン製品の分析 Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017
出版日: 2017年06月13日 ページ情報: 英文 258 Pages
概要

消化管間質腫瘍 (GIST) とは、消化管に生じる腫瘍の一種です。軟部組織肉腫とよばれるがんの一群に属し、良性腫瘍の場合もあれば、悪性の場合もあります。主な症状として、腹部の疼痛や不快感、手で触って感じられる腹部のかたまり、吐き気・嘔吐、吐血、血の混じった排便、頭痛に伴う倦怠感(赤血球不足)などが挙げられます。主な治療法には、外科手術や放射線治療、標的療法、化学療法などが含まれています。

当レポートでは、世界各国での消化管間質腫瘍 (GIST) 治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

消化管間質腫瘍 (GIST)の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

消化管間質腫瘍 (GIST):企業で開発中の治療薬

消化管間質腫瘍 (GIST):大学/機関で研究中の治療薬

消化管間質腫瘍 (GIST):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

消化管間質腫瘍 (GIST):企業で開発中の製品

消化管間質腫瘍 (GIST):大学/機関で研究中の製品

消化管間質腫瘍 (GIST)の治療薬開発に従事している企業

  • AB Science SA
  • Advenchen Laboratories, LLC
  • Ariad Pharmaceuticals, Inc.
  • Arog Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Blueprint Medicines Corporation
  • Boston Biomedical, Inc.
  • Calithera Biosciences, Inc.
  • Chipscreen Biosciences Ltd
  • Deciphera Pharmaceuticals, LLC
  • F. Hoffmann-La Roche Ltd.
  • Horizon Pharma Plc
  • Immunicum AB
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Kolltan Pharmaceuticals, Inc.
  • Natco Pharma Limited
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • Omeros Corporation
  • Plexxikon Inc.
  • TG Therapeutics, Inc.
  • Threshold Pharmaceuticals, Inc.

消化管間質腫瘍 (GIST):治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

消化管間質腫瘍 (GIST):最近のパイプライン動向

消化管間質腫瘍 (GIST):休止中のプロジェクト

消化管間質腫瘍 (GIST):開発が中止された製品

消化管間質腫瘍 (GIST):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9399IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 16, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Gastrointestinal Stromal Tumor (GIST) - Overview 8
  • Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development 9
  • Pipeline Overview 9
  • Pipeline by Companies 10
  • Pipeline by Universities/Institutes 13
  • Products under Development by Companies 14
  • Products under Development by Universities/Institutes 16
  • Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 17
  • Assessment by Target 17
  • Assessment by Mechanism of Action 20
  • Assessment by Route of Administration 23
  • Assessment by Molecule Type 25
  • Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 27
  • AB Science SA 27
  • Advanced Accelerator Applications SA 27
  • Advenchen Laboratories LLC 28
  • Ariad Pharmaceuticals Inc 28
  • Arog Pharmaceuticals Inc 29
  • ArQule Inc 29
  • Array BioPharma Inc 30
  • Astex Pharmaceuticals Inc 30
  • Blueprint Medicines Corp 31
  • Boston Biomedical Inc 31
  • Calithera Biosciences Inc 32
  • Celldex Therapeutics Inc 32
  • Chipscreen Biosciences Ltd 33
  • CytRx Corp 33
  • Deciphera Pharmaceuticals LLC 34
  • Exelixis Inc 34
  • F. Hoffmann-La Roche Ltd 35
  • Hanmi Pharmaceuticals Co Ltd 35
  • Horizon Pharma Plc 36
  • Immunicum AB 36
  • Jiangsu Hengrui Medicine Co Ltd 37
  • Natco Pharma Ltd 37
  • Nerviano Medical Sciences Srl 38
  • Novartis AG 38
  • Omeros Corp 39
  • Pharma Mar SA 39
  • Plexxikon Inc 40
  • Rhizen Pharmaceuticals SA 40
  • Taiho Pharmaceutical Co Ltd 41
  • Gastrointestinal Stromal Tumor (GIST) - Drug Profiles 42
  • aldoxorubicin hydrochloride - Drug Profile 42
  • amcasertib - Drug Profile 59
  • apatinib - Drug Profile 62
  • ARQ-092 - Drug Profile 67
  • binimetinib - Drug Profile 70
  • BLU-285 - Drug Profile 79
  • buparlisib hydrochloride - Drug Profile 83
  • cabozantinib s-malate - Drug Profile 89
  • CB-839 - Drug Profile 108
  • CDX-0158 - Drug Profile 116
  • CHMFLKIT-110 - Drug Profile 119
  • crenolanib besylate - Drug Profile 120
  • CS-2164 - Drug Profile 124
  • dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 125
  • DCC-2618 - Drug Profile 133
  • everolimus - Drug Profile 135
  • HM-95573 - Drug Profile 147
  • interferon gamma-1b - Drug Profile 149
  • Intuvax - Drug Profile 154
  • masitinib - Drug Profile 160
  • nilotinib - Drug Profile 176
  • NMSP-088 - Drug Profile 182
  • NRCAN-019 - Drug Profile 183
  • onalespib - Drug Profile 185
  • Peptide to Antagonize GRPR for Oncology - Drug Profile 189
  • pexidartinib - Drug Profile 190
  • PLX-9486 - Drug Profile 195
  • PM-184 - Drug Profile 196
  • ponatinib hydrochloride - Drug Profile 198
  • SF-1126 - Drug Profile 214
  • SHR-1020 - Drug Profile 216
  • Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile 218
  • Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 219
  • TAS-116 - Drug Profile 220
  • TGR-1202 - Drug Profile 221
  • vemurafenib - Drug Profile 230
  • WBZ-4 - Drug Profile 237
  • Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 238
  • Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 239
  • Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 240
  • Featured News & Press Releases 240
  • Appendix 255
  • Methodology 255
  • Coverage 255
  • Secondary Research 255
  • Primary Research 255
  • Expert Panel Validation 255
  • Contact Us 255
  • Disclaimer 256

List of Tables

  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications SA, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by CytRx Corp, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Ltd, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences Srl, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corp, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pharma Mar SA, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top